Coherus BioSciences Q4 2023 Adj EPS $(0.62) Misses $(0.12) Estimate, Sales $91.524M Miss $96.400M Estimate
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences (NASDAQ:CHRS) reported Q4 2023 adjusted EPS of $(0.62), missing the $(0.12) estimate, with sales of $91.524M also missing the $96.400M estimate. This represents a 101.81% increase in sales compared to the same period last year.
March 13, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Coherus BioSciences reported a significant miss in both adjusted EPS and sales for Q4 2023, with adjusted EPS missing estimates by 416.67% and sales missing by 5.06%, despite a 101.81% increase in sales YOY.
The significant miss in both EPS and sales estimates for Q4 2023 is likely to negatively impact investor sentiment and could lead to a short-term decrease in CHRS stock price. The miss in EPS by a wide margin is particularly concerning, despite the notable year-over-year sales growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100